SML2743

TM30089

≥98% (HPLC)

• Synonym(s): 2-(3-(4-Fluoro-N-methylphenylsulfonamido)-3,4-dihydro-1H-carbazol-9(2H)-yl)acetic acid, 3-[[(4-Fluorophenyl)sulfonyl]methylamino]-1,2,3,4-tetrahydro-9H-carbazole-9-acetic acid, CAY 10471, CAY-10471, CAY10471, TM 30089, TM-30089, {3-[(4-Fluorobenzenesulfonyl)methylamino]-1,2,3,4-tetrahydrocarbazol-9-yl}acetic acid
• Empirical Formula (Hill Notation): C₂₁H₂₁FN₂O₄S
• CAS Number: 844639-57-2
• Molecular Weight: 416.47
• MDL number: MFCD08062186

Properties

• Quality Level: 100
• Assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C
• InChI: 1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-15)17-4-2-3-5-19(17)24(20)13-21(25)26/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)
• InChI key: CANCTKXGRVNXFP-UHFFFAOYSA-N

Description

Biochem/physiol Actions

TM30089 is a ramatroban analog and an orally active, high-affinity, potent and selective prostaglandin D2 receptor 2 (DP2; CRTH2) antagonist (K_i = 0.6 nM/hDP2 against 1.2 nM PGD2; K_i = 1.2 μM/hDP1 against 0.5 nM PGD2, >10 μM/hTP against 5 nM SQ29548) that blocks PGD2-induced responses in hDP2 transfectants (IP1/βarr IC₅₀ = 1.2/3.0 nM) and exhibits in vivo efficacy in a murine model of renal tubulointerstitial fibrosis (20 mg/kg b.i.d. p.o., starting 4 days before or 3 days after unilateral ureteral obstruction/UUO).

Safety Information

• Pictograms: GHS07,GHS09
• Signal Word: Warning
• Hazard Statements: H315 - H317 - H319 - H410
• Precautionary Statements: P273 - P280 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3